77 results
8-K
EX-1.1
EYPT
EyePoint Pharmaceuticals Inc
7 Dec 23
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
6:11pm
) are in material compliance with all statutes, rules and regulations applicable to the testing, development, manufacture, packaging, processing, use
8-K
EX-2.1
EYPT
EyePoint Pharmaceuticals Inc
18 May 23
EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties
7:06am
, packaging, labeling, quality assurance testing and release, shipping, and storage at manufacturing facilities of any pharmaceutical or biological … the [***] period following the Effective Date, and (ii) sell any inventory of YUTIQ purchased under the Commercial Supply Agreement with labeling and packaging
8-K
EX-10.1
EYPT
EyePoint Pharmaceuticals Inc
18 May 23
EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties
7:06am
of the Product intended for use in the United States.
1.7“Components” means, collectively, all packaging components, raw materials, ingredients, including … , and will include primary and secondary packaging, labeling and serialization.
ARTICLE 4.
QUALITY CONTROL; INSPECTIONS
4.1Quality Control. EyePoint
8-K
EX-1.1
tnrvgu wdmtsbb5xvde
19 Nov 21
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
4:01pm
8-K
EX-1.1
mkx4q
3 Feb 21
Entry into a Material Definitive Agreement
4:11pm
8-K
EX-1.1
2itxu
5 Aug 20
Entry into a Material Definitive Agreement
8:21am
8-K
EX-1.1
gyslm
24 Feb 20
Entry into a Material Definitive Agreement
4:05pm
8-K
EX-99.1
ekx5t1f
20 Feb 20
Other Events
4:02pm
8-K/A
EX-99.1
qpi1zxhv
16 Jan 20
Other Events
11:58am
8-K
EX-99.1
nd1d6nt2r4gv wl16
14 Jan 20
Other Events
12:00am
8-K
EX-99.1
x777w8
27 Nov 19
Other Events
5:22pm
8-K
EX-1.1
ume 7k1hx2wmge
1 Apr 19
Entry into a Material Definitive Agreement
5:01pm
10-KT
etkt662mb4 d8g
18 Mar 19
Annual report (with FYE transition)
5:30pm